1.FEBS Open Bio. 2022 Jul;12(7):1268-1285.
2.Epub 2022 Jun 9. Eur Cytokine Netw. 2004 Jul-Sep;15(3):255-62.2.Semin Immunol. 2021 Apr:54:101512.
3.Epub 2021 Nov 8.3.Biotechnol Lett. 2003 Feb;25(3):205-11.
As key factors in hematopoietic development, G-CSF/GM-CSF are well-known facilitators of myelopoiesis and mobilization of hematopoietic stem cells (HSCs). In addition, these two cytokines can also promote or inhibit tumors, dependent on tumor type. In multiple cancer types, hematopoiesis is greatly enhanced and abnormal lineage differentiation is induced by these two cytokines. Numerous preclinical studies have reported a pro-tumour role for granulocyte colony-stimulating factor (G-CSF) that is predominantly mediated by neutrophils and MDSCs, the major G-CSF receptor expressing populations. Granulocyte-Macrophage colony stimulating factor (GM-CSF) and Granulocyte colony stimulating factor (G-CSF) are cytokines involved in the differentiation of bone marrow progenitor cells into myeloid cells. They also activate mature myeloid cells to mediate a variety of antimicrobial activities and inflammatory responses. Recombinant GM-CSF and G-CSF proteins have been used to treat various diseases including cancer and hematopoietic diseases and to isolate peripheral blood progenitor cells for bone marrow transplantation.
Measured in a cell proliferation assay using Murine M-NFS-60 cells, the EC50 for this effect is less than 0.03ng/ml.
2μg (R: reducing condition, N: non-reducing condition).